Skip to main content
Ciara Curtin on Muck Rack

Ciara Curtin

Verified
Atlanta
As seen in: GenomeWeb, Scientific American, Modern Healthcare, Spectrum, 360Dx, Precision Medicine Online, Precision Oncology News
I am a science writer and editor. I also like food, running, and yoga. All views expressed here are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ciara

Contact Ciara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Human Embryo Base Editing Study Sheds Light on Early Development, Sparks Concerns

|
By Ciara Curtin Verified
| GenomeWeb Verified
NEW YORK – University of Cambridge researchers have used base editing in human embryos to study the role of a transcription factor in early development. While their focus was on basic biology, it still raises concerns about the possibility of a future use of the technology to change the genetic makeup of embryos.
Open in Who Shared Issue with article?

Human Embryo Base Editing Study Sheds Light on Early Development, Sparks Concerns

|
By Ciara Curtin Verified
| Precision Medicine Online Verified
NEW YORK – University of Cambridge researchers have used base editing in human embryos to study the role of a transcription factor in early development. While their focus was on basic biology, it still raises concerns about the possibility of a future use of the technology to change the genetic makeup of embryos.
Open in Who Shared Issue with article?

CAR T-Cell Therapy Increases Survival Rates in MRD-Positive, High-Risk Pediatric B-ALL Patients

|
By Ciara Curtin Verified
| Precision Medicine Online Verified
NEW YORK – High-risk pediatric B-cell acute lymphoblastic leukemia patients who are minimal residual disease-positive at the end of first-line induction and consolidation therapy had increased survival rates when treated with Novartis' CAR T-cell therapy Kymriah (tisagenlecleucel), according to data presented at the American Society of Clinical Oncology's annual meeting Sunday.
Open in Who Shared Issue with article?
See all 112 articles